216 related articles for article (PubMed ID: 16305662)
41. Ovarian tumour antigens as potential targets for immune gene therapy.
Kuiper M; Peakman M; Farzaneh F
Gene Ther; 1995 Jan; 2(1):7-15. PubMed ID: 7712335
[TBL] [Abstract][Full Text] [Related]
42. Ovarian cancer creates a suppressive microenvironment to escape immune elimination.
Yigit R; Massuger LF; Figdor CG; Torensma R
Gynecol Oncol; 2010 May; 117(2):366-72. PubMed ID: 20144842
[TBL] [Abstract][Full Text] [Related]
43. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
44. Tregs and rethinking cancer immunotherapy.
Curiel TJ
J Clin Invest; 2007 May; 117(5):1167-74. PubMed ID: 17476346
[TBL] [Abstract][Full Text] [Related]
45. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.
Ruter J; Barnett BG; Kryczek I; Brumlik MJ; Daniel BJ; Coukos G; Zou W; Curiel TJ
Front Biosci (Landmark Ed); 2009 Jan; 14(5):1761-70. PubMed ID: 19273160
[TBL] [Abstract][Full Text] [Related]
46. Prostate cancer immunology: biology, therapeutics, and challenges.
Webster WS; Small EJ; Rini BI; Kwon ED
J Clin Oncol; 2005 Nov; 23(32):8262-9. PubMed ID: 16278482
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy approaches targeting regulatory T-cells.
Onishi H; Morisaki T; Katano M
Anticancer Res; 2012 Mar; 32(3):997-1003. PubMed ID: 22399623
[TBL] [Abstract][Full Text] [Related]
49. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies.
Nicodemus CF; Schultes BC; Hamilton BL
Expert Rev Vaccines; 2002 Jun; 1(1):35-48. PubMed ID: 12908511
[TBL] [Abstract][Full Text] [Related]
50. Novel tumor immunotherapy: Targeting dysfunctional antigen presenting cells.
Wei S; Kryczek I; Zou L; Curiel T; Cheng P; Zou W
Discov Med; 2005 Oct; 5(29):489-92. PubMed ID: 20704848
[TBL] [Abstract][Full Text] [Related]
51. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
Chekmasova AA; Brentjens RJ
Discov Med; 2010 Jan; 9(44):62-70. PubMed ID: 20102688
[TBL] [Abstract][Full Text] [Related]
52. Parity improves anti-tumor immunity in breast cancer patients.
Krause AL; Schuetz F; Boudewijns M; Pritsch M; Wallwiener M; Golatta M; Rom J; Heil J; Sohn C; Schneeweiss A; Beckhove P; Domschke C
Oncotarget; 2017 Dec; 8(62):104981-104991. PubMed ID: 29285226
[TBL] [Abstract][Full Text] [Related]
53. Immunological treatment of ovarian cancer.
Cannon MJ; Santin AD; O'Brien TJ
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):87-92. PubMed ID: 15128013
[TBL] [Abstract][Full Text] [Related]
54. Immunologic principles and immunotherapeutic approaches in ovarian cancer.
Knutson KL; Curiel TJ; Salazar L; Disis ML
Hematol Oncol Clin North Am; 2003 Aug; 17(4):1051-73. PubMed ID: 12959191
[TBL] [Abstract][Full Text] [Related]
55. The potential value of cancer-testis antigens in ovarian cancer: Prognostic markers and targets for immunotherapy.
Lin L; Zou X; Nong W; Ge Y; Li F; Luo B; Zhang Q; Xie X
Immun Inflamm Dis; 2024 Jun; 12(6):e1284. PubMed ID: 38896069
[TBL] [Abstract][Full Text] [Related]
56. The role of regulatory T cells in ovarian cancer.
Dietl J; Engel JB; Wischhusen J
Int J Gynecol Cancer; 2007; 17(4):764-70. PubMed ID: 17309663
[TBL] [Abstract][Full Text] [Related]
57. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
Sachamitr P; Hackett S; Fairchild PJ
Front Immunol; 2014; 5():176. PubMed ID: 24860566
[TBL] [Abstract][Full Text] [Related]
58. Cellular immunotherapy for ovarian cancer.
Cannon MJ; O'Brien TJ
Expert Opin Biol Ther; 2009 Jun; 9(6):677-88. PubMed ID: 19456205
[TBL] [Abstract][Full Text] [Related]
59. Advances and prospects in adoptive cell transfer therapy for ovarian cancer.
Urbanska K; Powell DJ
Immunotherapy; 2015; 7(5):473-6. PubMed ID: 26065472
[No Abstract] [Full Text] [Related]
60. Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities.
Cassar E; Kartikasari AER; Plebanski M
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
